Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA
Genetic sequencing of malignancies has become increasingly important to uncover therapeutic targets and capture the tumor’s dynamic changes to drug sensitivity and resistance through genomic evolution. In lung cancers, the current standard of tissue biopsy at the time of diagnosis and progression is...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2017-01-01
|
Series: | Journal of Oncology |
Online Access: | http://dx.doi.org/10.1155/2017/4517834 |
id |
doaj-19ccd9777f2f45499b3443a9dedcef30 |
---|---|
record_format |
Article |
spelling |
doaj-19ccd9777f2f45499b3443a9dedcef302020-11-24T21:41:36ZengHindawi LimitedJournal of Oncology1687-84501687-84692017-01-01201710.1155/2017/45178344517834Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNAMichael Offin0Jacob J. Chabon1Pedram Razavi2James M. Isbell3Charles M. Rudin4Maximilian Diehn5Bob T. Li6Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USAInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA 94305, USADepartment of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USAThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USAThoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USAInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA 94305, USAThoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USAGenetic sequencing of malignancies has become increasingly important to uncover therapeutic targets and capture the tumor’s dynamic changes to drug sensitivity and resistance through genomic evolution. In lung cancers, the current standard of tissue biopsy at the time of diagnosis and progression is not always feasible or practical and may underestimate intratumoral heterogeneity. Technological advances in genetic sequencing have enabled the use of circulating tumor DNA (ctDNA) analysis to obtain information on both targetable mutations and capturing real-time Darwinian evolution of tumor clones and drug resistance mechanisms under selective therapeutic pressure. The ability to analyze ctDNA from plasma, CSF, or urine enables a comprehensive view of cancers as systemic diseases and captures intratumoral heterogeneity. Here, we describe these recent advances in the setting of lung cancers and advocate for further research and the incorporation of ctDNA analysis in clinical trials of targeted therapies. By capturing genomic evolution in a noninvasive manner, liquid biopsy for ctDNA analysis could accelerate therapeutic discovery and deliver the next leap forward in precision medicine for patients with lung cancers and other solid tumors.http://dx.doi.org/10.1155/2017/4517834 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Michael Offin Jacob J. Chabon Pedram Razavi James M. Isbell Charles M. Rudin Maximilian Diehn Bob T. Li |
spellingShingle |
Michael Offin Jacob J. Chabon Pedram Razavi James M. Isbell Charles M. Rudin Maximilian Diehn Bob T. Li Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA Journal of Oncology |
author_facet |
Michael Offin Jacob J. Chabon Pedram Razavi James M. Isbell Charles M. Rudin Maximilian Diehn Bob T. Li |
author_sort |
Michael Offin |
title |
Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA |
title_short |
Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA |
title_full |
Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA |
title_fullStr |
Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA |
title_full_unstemmed |
Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA |
title_sort |
capturing genomic evolution of lung cancers through liquid biopsy for circulating tumor dna |
publisher |
Hindawi Limited |
series |
Journal of Oncology |
issn |
1687-8450 1687-8469 |
publishDate |
2017-01-01 |
description |
Genetic sequencing of malignancies has become increasingly important to uncover therapeutic targets and capture the tumor’s dynamic changes to drug sensitivity and resistance through genomic evolution. In lung cancers, the current standard of tissue biopsy at the time of diagnosis and progression is not always feasible or practical and may underestimate intratumoral heterogeneity. Technological advances in genetic sequencing have enabled the use of circulating tumor DNA (ctDNA) analysis to obtain information on both targetable mutations and capturing real-time Darwinian evolution of tumor clones and drug resistance mechanisms under selective therapeutic pressure. The ability to analyze ctDNA from plasma, CSF, or urine enables a comprehensive view of cancers as systemic diseases and captures intratumoral heterogeneity. Here, we describe these recent advances in the setting of lung cancers and advocate for further research and the incorporation of ctDNA analysis in clinical trials of targeted therapies. By capturing genomic evolution in a noninvasive manner, liquid biopsy for ctDNA analysis could accelerate therapeutic discovery and deliver the next leap forward in precision medicine for patients with lung cancers and other solid tumors. |
url |
http://dx.doi.org/10.1155/2017/4517834 |
work_keys_str_mv |
AT michaeloffin capturinggenomicevolutionoflungcancersthroughliquidbiopsyforcirculatingtumordna AT jacobjchabon capturinggenomicevolutionoflungcancersthroughliquidbiopsyforcirculatingtumordna AT pedramrazavi capturinggenomicevolutionoflungcancersthroughliquidbiopsyforcirculatingtumordna AT jamesmisbell capturinggenomicevolutionoflungcancersthroughliquidbiopsyforcirculatingtumordna AT charlesmrudin capturinggenomicevolutionoflungcancersthroughliquidbiopsyforcirculatingtumordna AT maximiliandiehn capturinggenomicevolutionoflungcancersthroughliquidbiopsyforcirculatingtumordna AT bobtli capturinggenomicevolutionoflungcancersthroughliquidbiopsyforcirculatingtumordna |
_version_ |
1725921160740208640 |